Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 2/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7285160 | 1.00 | CTSK (0.61) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL18562066 | 1.00 | CTSK (0.61) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL25015110 | 1.00 | CTSK (0.61) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL15671593 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL22371979 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL3087516 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL22371978 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL22371977 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL7345607 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL7018649 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656248-A2 | ANTI-C-MET ANTIBODY DRUG CONJUGATES | AbbVie Manufacturing Management Unlimited Company (IE) | 2025-12-03 | — | — | EP | disclosed |
| EP-4217398-B1 | ANTI-C-MET ANTIBODY DRUG CONJUGATES | ABBVIE MFG MANAGEMENT UNLIMITED COMPANY (IE) | 2025-09-24 | — | — | EP | disclosed |
| US-20240247030-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | JPMORGAN CHASE BANK, N.A. | 2024-07-25 | — | — | US | disclosed |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-3900742-B1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEAGEN INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240091374-A1 | ANTI-SEZ6 ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024042497-A1 | ANTI-SEZ6 ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4327832-A1 | ANTI-SEZ6 ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230372519-A1 | ANTI-C-MET ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2019109188-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-06-13 | — | — | WO | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3383420-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | Seattle Genetics, Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| CN-108367043-A | The conjugate of quaternized tubulysin compound | 西雅图基因公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-104703991-B | Macrocyclic Inhibitors of Flaviviridae Viruses | 吉利德科学公司 | 2018-03-23 | — | — | CN | disclosed |
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3191502-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | Seattle Genetics, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2017096311-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| EP-2861604-B1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2017-03-01 | — | — | EP | disclosed |
| WO-2016040684-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | CD47, CD44, MSR1 | CTSK 3383/4885CTSS 3176/4885PSENEN 2778/4885 |
| US-20240247030-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | CD47, CD44, MSR1 | CTSK 3383/4885CTSS 3176/4885PSENEN 2778/4885 |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CTSK 1371/4885CTSS 2029/4885PSENEN 4222/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | CTSK 1371/4885CTSS 2029/4885PSENEN 4222/4885 |
| US-20230372519-A1 | ANTI-C-MET ANTIBODY DRUG CONJUGATES | MET, HGFAC, MMAB | CTSK 1814/4885CTSS 1662/4885PSENEN 3033/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | CTSK 1371/4885CTSS 2029/4885PSENEN 4222/4885 |
| US-20240091374-A1 | ANTI-SEZ6 ANTIBODY DRUG CONJUGATES | EPHA6, EZH2, EPHB6 | CTSK 3496/4885CTSS 3322/4885PSENEN 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.